CTOs on the Move


 
Kryo, Inc. is the world`s leading innovator of temperature-regulated and climate-control sleep solutions engineered to optimize health and wellness through enhanced quality sleep and patented technology. Kryo ranks no. 615 on the 2020 Inc. 5000 list.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.kryoinc.com
  • 144 Talbert Pointe Dr
    Mooresville, NC USA 28117
  • Phone: 704.235.6831

Executives

Name Title Contact Details

Funding

Kryo raised $20M on 12/23/2020

Similar Companies

Bardavon

Bardavon Health Innovations is a proactive Workers` Compensation partner that connects all stakeholders to better manage claims. We offer work readiness solutions through rehabilitation therapy. We share a holistic analysis of the claim so America`s injured workers can achieve optimized functional outcomes and return to full-duty.

Cardiovascular Associates

Cardiovascular Associates is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Birmingham, AL. To find more information about Cardiovascular Associates, please visit www.cvapc.com

Handbooks in Health Care Company

Handbooks in Health Care Company is a Newtown, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mercy Health System

Mercy Health System is the largest Catholic healthcare system serving the Delaware Valley and is a member of Catholic Health East, a multi-institutional, Catholic health system co-sponsored by 13 religious congregations and Hope Ministries.

FibroGen

FibroGen is a research-based biotechnology company using its expertise in connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology to discover, develop, and commercialize novel therapeutics for serious unmet medical needs. FibroGen’s research team is committed to discovering novel therapies in areas of major unmet medical need. Our goal is to continue to provide pipeline candidates supported by rigorous data in well-characterized therapeutic settings. All of FibroGen`s therapeutic candidates have been internally developed based on FibroGen`s pioneering research in two important areas of biology, hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF).